title: Imatinib mesylate induced immune thrombocytopenia.
authors.forename: Senthil
authors.initials: S
authors.lastname: Rajappa
authors.forename: Lalit
authors.initials: L
authors.lastname: Varadpande
authors.forename: Tara Roshni
authors.initials: TR
authors.lastname: Paul
authors.forename: Raghunadharao
authors.initials: R
authors.lastname: Digumarti
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008297:Male; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use*; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000209:etiology*; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate